TWI891696B - 新穎之化合物 - Google Patents

新穎之化合物

Info

Publication number
TWI891696B
TWI891696B TW109145642A TW109145642A TWI891696B TW I891696 B TWI891696 B TW I891696B TW 109145642 A TW109145642 A TW 109145642A TW 109145642 A TW109145642 A TW 109145642A TW I891696 B TWI891696 B TW I891696B
Authority
TW
Taiwan
Prior art keywords
oxadiazol
acrylic acid
methyl
meth
phenyl
Prior art date
Application number
TW109145642A
Other languages
English (en)
Chinese (zh)
Other versions
TW202138356A (zh
Inventor
麥可 庫克
大衛 卡什
馬修 費菲
湯瑪斯 沃
薩利赫 艾哈邁德
亞歷西奧 德西蒙妮
貝瑞 特奧包德
Original Assignee
英商喜翠克斯治療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商喜翠克斯治療有限公司 filed Critical 英商喜翠克斯治療有限公司
Publication of TW202138356A publication Critical patent/TW202138356A/zh
Application granted granted Critical
Publication of TWI891696B publication Critical patent/TWI891696B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
TW109145642A 2019-12-23 2020-12-23 新穎之化合物 TWI891696B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP19219531.1 2019-12-23
EP19219531 2019-12-23
EP20162545.6 2020-03-11
EP20162545 2020-03-11
EP20189623 2020-08-05
EP20189623.0 2020-08-05
EP20205768 2020-11-04
EP20205768.3 2020-11-04

Publications (2)

Publication Number Publication Date
TW202138356A TW202138356A (zh) 2021-10-16
TWI891696B true TWI891696B (zh) 2025-08-01

Family

ID=74104118

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109145642A TWI891696B (zh) 2019-12-23 2020-12-23 新穎之化合物

Country Status (29)

Country Link
EP (2) EP4081511B3 (https=)
JP (2) JP7679384B2 (https=)
KR (1) KR20220119425A (https=)
CN (1) CN115066418B (https=)
AU (1) AU2020412853A1 (https=)
BR (1) BR112022011933A2 (https=)
CA (2) CA3161424C (https=)
CL (1) CL2022001722A1 (https=)
CO (1) CO2022008652A2 (https=)
CR (1) CR20220300A (https=)
DK (1) DK4081511T3 (https=)
EC (1) ECSP22049370A (https=)
ES (1) ES2987014T3 (https=)
FI (1) FI4081511T3 (https=)
HR (1) HRP20241378T1 (https=)
HU (1) HUE068571T2 (https=)
IL (1) IL293982B2 (https=)
JO (1) JOP20220162A1 (https=)
LT (1) LT4081511T (https=)
MA (1) MA58170B1 (https=)
MD (1) MD4081511T2 (https=)
MX (1) MX2022007846A (https=)
PE (1) PE20221584A1 (https=)
PH (1) PH12022551546A1 (https=)
PL (1) PL4081511T4 (https=)
RS (1) RS66019B1 (https=)
SI (1) SI4081511T1 (https=)
TW (1) TWI891696B (https=)
WO (1) WO2021130492A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013299A (es) 2019-04-30 2022-01-31 Sitryx Therapeutics Ltd Derivados de acido itaconico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunitaria indeseable.
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
EP4192821A1 (en) 2020-08-05 2023-06-14 Sitryx Therapeutics Limited Alpha,beta unsaturated methacrylic esters with anti-inflammatory properties
EP4330231A1 (en) * 2021-04-26 2024-03-06 Sitryx Therapeutics Limited 2-methylene-4-oxo-butanoic acid drivatives for the treatment of inflammation
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4359390A1 (en) * 2021-06-22 2024-05-01 Sitryx Therapeutics Limited Acrylamide derivatives useful as anti-inflammatory agents
CN113499453B (zh) * 2021-07-20 2022-10-21 徐州医科大学 自噬抑制及抗炎联合温合光热诊疗剂及其制备方法与应用
US20240360067A1 (en) 2021-08-11 2024-10-31 Sitryx Therapeutics Limited Derivatives of itaconic acid and their use as anti-inflammatory agents
AU2023287566A1 (en) 2022-06-22 2025-01-16 Sitryx Therapeutics Limited Oxadiazole derivatives, preparation process thereof and their use in treating inflammatory diseases
WO2024089421A1 (en) 2022-10-25 2024-05-02 Sitryx Therapeutics Limited Tetrazole derivatives
CN120712258A (zh) 2022-12-15 2025-09-26 西特瑞治疗有限公司 用于治疗或预防炎性疾病或与不良免疫反应相关的疾病的取代吡啶类化合物
KR102864655B1 (ko) * 2023-01-19 2025-09-29 대한민국 뎅기바이러스 감염에 의한 질환의 예방 또는 치료용 약학적 조성물
CN115819186B (zh) * 2023-02-14 2023-05-16 广东银珠医药科技有限公司 一种3,5-二氯苯甲醇的新型制备方法
CN117205194A (zh) * 2023-05-10 2023-12-12 苏州大学 衣康酸或其衍生物在制备预防或治疗急性移植物抗宿主病药物中的应用
CN116725998A (zh) * 2023-07-20 2023-09-12 中国科学技术大学 特立氟胺在抑制nlrp3炎症小体活化中的应用
CN119792264B (zh) * 2025-03-14 2025-06-10 华中科技大学同济医学院附属同济医院 丁酰肼在制备预防或治疗copd的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207889A1 (en) * 1996-08-07 2003-11-06 Owen David Alan Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
US20120142717A1 (en) * 2010-12-06 2012-06-07 Yun Jin Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011235A1 (en) * 1993-10-20 1995-04-27 The Upjohn Company Pyrimidinones as antiarthritic and anti-inflammatories
TW201206429A (en) * 2010-07-08 2012-02-16 Merck Serono Sa Substituted oxadiazole derivatives
KR102085557B1 (ko) 2013-03-14 2020-03-06 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
WO2014152263A1 (en) * 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
AU2014290368B2 (en) * 2013-07-18 2019-07-11 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
CN103923105B (zh) * 2014-04-17 2016-08-24 北京大学 2-中氮茚甲酰胺类化合物及其制备和用途
EP3416634A4 (en) 2016-02-15 2019-10-09 Artyomov, Maxim IMMUNOMODULATORY AGENTS AND METHOD FOR USE THEREOF
WO2019036509A1 (en) 2017-08-14 2019-02-21 Washington University METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH CANCER, INFLAMMATION OR IMMUNE RESPONSE
CN110731955B (zh) 2019-10-28 2023-05-02 中山大学 衣康酸二甲酯在预防和治疗溃疡性结肠炎及其癌变中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207889A1 (en) * 1996-08-07 2003-11-06 Owen David Alan Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
US20120142717A1 (en) * 2010-12-06 2012-06-07 Yun Jin Compounds

Also Published As

Publication number Publication date
JP2025131581A (ja) 2025-09-09
EP4081511A1 (en) 2022-11-02
SI4081511T1 (sl) 2024-12-31
PH12022551546A1 (en) 2023-05-03
CL2022001722A1 (es) 2023-03-03
EP4442319A3 (en) 2025-01-15
MX2022007846A (es) 2022-07-19
EP4081511B3 (en) 2026-03-04
US20230219907A1 (en) 2023-07-13
CR20220300A (es) 2022-08-23
MA58170B1 (fr) 2024-10-31
MD4081511T2 (ro) 2025-01-31
CA3161424C (en) 2025-10-21
AU2020412853A1 (en) 2022-05-26
IL293982A (en) 2022-08-01
EP4442319A2 (en) 2024-10-09
HRP20241378T1 (hr) 2025-01-03
CO2022008652A2 (es) 2022-07-19
CA3161424A1 (en) 2021-07-01
WO2021130492A1 (en) 2021-07-01
KR20220119425A (ko) 2022-08-29
RS66019B1 (sr) 2024-11-29
DK4081511T3 (da) 2024-09-23
PL4081511T4 (pl) 2024-12-09
CN115066418A (zh) 2022-09-16
IL293982B1 (en) 2025-04-01
JP2023508142A (ja) 2023-03-01
ES2987014T3 (es) 2024-11-13
JP7679384B2 (ja) 2025-05-19
BR112022011933A2 (pt) 2022-09-06
JOP20220162A1 (ar) 2023-01-30
LT4081511T (lt) 2024-10-25
HUE068571T2 (hu) 2025-01-28
ECSP22049370A (es) 2022-07-29
EP4081511B1 (en) 2024-07-31
CA3280359A1 (en) 2026-03-02
PL4081511T3 (pl) 2024-11-25
FI4081511T3 (fi) 2024-10-24
IL293982B2 (en) 2025-08-01
PE20221584A1 (es) 2022-10-06
CN115066418B (zh) 2025-09-05
TW202138356A (zh) 2021-10-16

Similar Documents

Publication Publication Date Title
TWI891696B (zh) 新穎之化合物
US12459908B2 (en) Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties
EP3962602A1 (en) Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response
EP4200275A2 (en) Fumarate derivatives and their medical use
US20230399289A1 (en) Itaconic acid derivatives
EP4359390A1 (en) Acrylamide derivatives useful as anti-inflammatory agents
EP4237404A1 (en) Novel compounds
KR20250136325A (ko) 염증성 질환 또는 바람직하지 않은 면역 반응과 연관된 질환을 치료 또는 예방하는 데 사용하기 위한 치환된 피리딘
US12617762B2 (en) Carboxy derivatives with antiinflamatory properties
EA048584B1 (ru) Карбоксипроизводные с противовоспалительными свойствами
HK40083255A (en) Carboxy derivatives with antiinflammatory properties
HK40083255B (en) Carboxy derivatives with antiinflammatory properties